权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vitro immunomodulation

评估环境潜力的研究

基本信息

批准号：
10906728
负责人：
FLORENCE BURLESON
金额：
$ 21.65万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-13 至 2024-08-12
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10906728
关键词：
Allergens Animals Autoimmune Diseases Biological Assay Blinded Chemical Agents Chemicals Code Collaborations Communicable Diseases Contracts Data Data Collection Dermal Development Event Exposure to Food Additives Gene Expression Profiling Hazard Identification Health Health Hazards Hematopoietic Human Human Cell Line Hypersensitivity Immunologic Techniques Immunologics Immunosuppression Immunotoxicology In Vitro Laboratories Measures Methods Molecular National Toxicology Program Neoplasms Peptides Pharmaceutical Preparations Predictive Value Preparation Reporting Research Resistance Skin Structure Techniques Testing Therapeutic Agents Validation Xenobiotics dietary supplements environmental agent exposed human population immune function immune system function immunoregulation immunotoxicity in vitro Model in vitro testing in vivo keratinocyte programs respiratory response screening

项目摘要

In vitro techniques for hazard identification for potential sensitizers have been of increasing importance to the NIEHS. A research collaboration agreement with a commercial vendor was established to assess the utility of the GARDair assay to identify respiratory sensitizers. As an extension of the previously reported agency partner studies where >200 chemicals were evaluated using in vitro methods to assess their potential to induce skin sensitization, NIEHS requested nominations from partner agencies to evaluate the use of an in vitro method to evaluate chemicals for their potential to induce allergic responses in the lung. The GARDair assay uses a gene set that has potential for identifying respiratory sensitizers. Agency partners nominated a total of 100 chemicals to be tested, including known respiratory sensitizers as well as chemicals of unknown potential to induce sensitization. BRT completed procurement of the chemicals in FY23 and the laboratory studies are ongoing. To date, 20 chemicals have passed range finder assays and the main runs are completed. NIEHS funded BRT participation in validation trials for the Electrophilic Allergen Screening Assay (EASA). This assay uses non-protein/peptide probes in a cell-free assessment to measure the ability of a test substance to “react” with biologically important molecules for the identification of electrophilic allergic contact dermatitis hazards. Data collection for these chemicals was completed in FY22 and the study method transfer and validation reports were completed and closed in FY23.

潜在致敏剂危害识别的体外技术对于 NIEHS 来说越来越重要。我们与一家商业供应商签订了研究合作协议，以评估 GARDair 检测方法识别呼吸道致敏物的效用。作为先前报道的机构合作伙伴研究的延伸，其中使用体外方法评估了超过 200 种化学品，以评估其诱发皮肤过敏的潜力，NIEHS 要求合作机构提名，以评估使用体外方法来评估化学品诱发肺部过敏反应的潜力。 GARDair 检测使用具有识别呼吸致敏剂潜力的基因组。机构合作伙伴提名了总共 100 种化学物质进行测试，包括已知的呼吸道致敏物以及未知潜在诱发致敏作用的化学物质。 BRT 在 2023 财年完成了化学品采购，实验室研究正在进行中。迄今为止，20 种化学品已通过测距仪检测，主要运行已完成。 NIEHS 资助 BRT 参与亲电过敏原筛查测定 (EASA) 的验证试验。该测定在无细胞评估中使用非蛋白质/肽探针来测量测试物质与生物学重要分子“反应”的能力，以识别亲电子过敏性接触性皮炎危害。这些化学品的数据收集已于 2022 财年完成，研究方法转移和验证报告已于 2023 财年完成并结束。